5 Most Promising Gene Editing Stocks According to Hedge Funds

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Investors In Q3 2023: 50

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company developing treatments for a wide variety of diseases such as those involving the eyes and the skin. The firm also focuses on treating colorectal cancer. The coming months might be crucial for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as the firm is seeking U.S. approval for a treatment for chronic obstructive pulmonary disorder (COPD).

As of September 2023 end, 50 out of the 910 hedge funds covered by Insider Monkey’s research were the firm’s shareholders. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s biggest investor among these is D. E. Shaw’s D E Shaw due to its $304 million stake.

Follow Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)